Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision: v3.5.2 added. Revision: v3.5.0 removed.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check46 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3; core study details appear unchanged.SummaryDifference0.1%

- Check75 days agoChange DetectedAn updated site revision tag (v3.4.2) was added, and an existing government funding status notice (v3.4.1) was removed. The study’s content and data remain unchanged.SummaryDifference0.4%

- Check82 days agoChange DetectedA government funding notice and status update were added to the page footer. The site revision label was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check89 days agoChange DetectedAdded a glossary toggle and updated metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0). Removed the older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4).SummaryDifference0.2%

Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.